A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18

• Status: Completed
• Trial end date: 2016-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of the regeneration treatment of tympanic membrane with NPC-18 and FBG-18.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan; Translational Research Informatics Center, Kobe, Hyogo, Japan
• Treatments: Fibrin Tissue Adhesive

Criteria

Inclusion Criteria:

1. Written informed concent obtained

2. At the time of obtaining informed consent, Ages ranged from over 20 to 80

3. At the time of obtaining informed consent, only those with tympanic membrane perforation in 1 ear (not both) for over 6 months (perforation in both ears is excluded)

Exclusion Criteria:

1. TMP caused by burn or radiation therapy

2. In patients with chronic otitis media with ear drum perforation, tympanic cavity are not dry

3. Inflammatory,infection or otorrhea in patient's eardrum,earcanal,middle ear and tympanic cavity

4. No invasion of epithelial and no cholesteatoma in tympanic cavity or around perforated edge

5. History of tympanoplasty

6. A Part of the eardrum adhered to tympanic cavity

7. By temporal bone CT, soft tissue shadow in mastoid antrum or tympanic (using a CT image of less than 12 wks before patients registration)

8. Abnormality in the chain and ear ossicles

9. Air-bone gap difference more than 25dB by patch hearing test

10. Unable to see whole edge of TMP due to narrow external auditory canal

11. Unable to wash out Ear drops during the treatment period

12. Presenting with uncontrolled diabetes (NGSP HbA1c 6.9% and more)

13. Presenting with autoimmune disease

14. History of malignancy within 3 years prior to obtained informed concent

15. Administration of immunosuppressive agent or anti-cancer-agent

16. History of Allergic reaction to local anesthetic(Xylocaine), bFGF(Fiblast spray), fibrin glue(Beriplast P Combi set, etc.), gelatin sponge formulation(spongel) and others

17. Though out the period from screening to treatment, patient who is unable to wash out "Thrombolytic agent", "Anticoagulant", "Anti-platelet agent", "Procoagulant agent", "anti-line solvent"and"aprotinin formulation"